Research square · 2026
The adult nasal mucosa is defined by distinct immune profiles that modulate in-vitro SARS-CoV-2 infection.
СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gowanlock Sarah N, Lam Victor Hk, Tepe Zeynep Güneş, Park Daniel E, Tai Vera, Salazar Juan E, Pham Tony, Khan Yazan, Nelson Sydney, Horn Caitlin, Zuanazzi David, Yang Diana, Price Lance B, Kaul Rupert, Sowerby Leigh, Troyer Ryan M, Liu Cindy M, Prodger Jessica L
Аннотация
BACKGROUND: The nasal mucosa is the primary entry site for many respiratory viruses, and immune molecules present at the time of exposure may dictate if infection occurs. However, the baseline immune state in healthy adults - and how it influences susceptibility to viruses - remains poorly defined.
METHODS: Levels of 16 immune molecules were measured in nasal secretions from two independent cohorts of healthy adults (total n = 166, Luminex). Participants were clustered based on normalized concentrations of immune analytes to identify profiles. An in vitro organotypic model of the nasal epithelium was used to examine the effect of immune profiles on SARS-CoV-2 infection: primary human nasal epithelial cells (n = 9 donors) were grown at air-liquid interface to induce mucociliary differentiation (42 days), treated with recombinant human cytokines (72 hours), and then challenged with wildtype SARS-CoV-2 Omicron BA.1 (24 hours). SARS-CoV-2 entry factor expression (post-cytokines, pre-challenge) and viral infection (N gene) were measured by qRT-PCR.
RESULTS: In both cohorts, a unique cluster was observed, characterized by distinctly high levels of antiviral interferons - particularly IFN-λ3 - with comparatively low levels of inflammatory chemokines and cytokines. In contrast, individuals with high overall levels of inflammatory mediators had absent IFN-λ3. In vitro, pretreatment with IFN-λ3 and IFN-α2, but not with pro-inflammatory cytokines, significantly reduced SARS-CoV-2 replication in differentiated nasal epithelial cultures, despite upregulating ACE2 expression.
CONCLUSIONS: Healthy adults exhibit distinct nasal immune profiles, with an IFN-λ3-dominant, low-inflammatory state conferring resistance to SARS-CoV-2 in vitro. The nasal immune milieu may influence susceptibility to respiratory viruses and the efficacy of mucosally administered vaccines.
METHODS: Levels of 16 immune molecules were measured in nasal secretions from two independent cohorts of healthy adults (total n = 166, Luminex). Participants were clustered based on normalized concentrations of immune analytes to identify profiles. An in vitro organotypic model of the nasal epithelium was used to examine the effect of immune profiles on SARS-CoV-2 infection: primary human nasal epithelial cells (n = 9 donors) were grown at air-liquid interface to induce mucociliary differentiation (42 days), treated with recombinant human cytokines (72 hours), and then challenged with wildtype SARS-CoV-2 Omicron BA.1 (24 hours). SARS-CoV-2 entry factor expression (post-cytokines, pre-challenge) and viral infection (N gene) were measured by qRT-PCR.
RESULTS: In both cohorts, a unique cluster was observed, characterized by distinctly high levels of antiviral interferons - particularly IFN-λ3 - with comparatively low levels of inflammatory chemokines and cytokines. In contrast, individuals with high overall levels of inflammatory mediators had absent IFN-λ3. In vitro, pretreatment with IFN-λ3 and IFN-α2, but not with pro-inflammatory cytokines, significantly reduced SARS-CoV-2 replication in differentiated nasal epithelial cultures, despite upregulating ACE2 expression.
CONCLUSIONS: Healthy adults exhibit distinct nasal immune profiles, with an IFN-λ3-dominant, low-inflammatory state conferring resistance to SARS-CoV-2 in vitro. The nasal immune milieu may influence susceptibility to respiratory viruses and the efficacy of mucosally administered vaccines.